Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2025-10-08
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is whether MRgART affects the heart differently than LINAC.
Participants will:
* Receive radiation therapy
* Undergo MRIs and bloodwork
* Complete quality of life questionnaires
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
NCT04183218
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
NCT07293247
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy
NCT00738452
Multi-catheter High Dose Rate (HDR) Breast Brachytherapy
NCT00214149
Radiation Induced Cardiopulmonary Injury in Humans
NCT02259452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MRgART radiation therapy
Participants randomized to this arm will receive magnetic resonance-guided adaptive radiation therapy (MRgART)
MRgART
Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
LINAC radiation therapy
Participants randomized to this arm will receive linear accelerator (LINAC) radiation therapy
LINAC
Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRgART
Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
LINAC
Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dosimetric eligibility criteria met using endpoints from QUANTEC (\>10% of heart receives \> 25 Gy) as determined through rapid auto-planning
* Participants with histologically or cytologically proven AJCC, 8th edition including:
* Stage IIIA,IIIB, or IIIC non-operable non-small cell lung cancer
* Stage I-III N0-2 disease esophageal/esophagogastric cancer
* Stage II or III thymoma/thymic carcinoma
* Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria.
* Participants must have a definitive course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction
Exclusion Criteria
* Prior thoracic radiotherapy significantly overlapping the heart region
* Contraindications to MRI
* Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carri Glide-Hurst, PhD, DABR, FAAPM
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin - Madison
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A533300
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH/HUMAN ONCOLOGY/HUMAN ONCO
Identifier Type: OTHER
Identifier Source: secondary_id
Protocol Version 10/31/2025
Identifier Type: OTHER
Identifier Source: secondary_id
2025-0798
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.